HK1082739A1 - Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction - Google Patents

Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction

Info

Publication number
HK1082739A1
HK1082739A1 HK06105215A HK06105215A HK1082739A1 HK 1082739 A1 HK1082739 A1 HK 1082739A1 HK 06105215 A HK06105215 A HK 06105215A HK 06105215 A HK06105215 A HK 06105215A HK 1082739 A1 HK1082739 A1 HK 1082739A1
Authority
HK
Hong Kong
Prior art keywords
disorder
metabolite
inhibitor
symptom
disease
Prior art date
Application number
HK06105215A
Other languages
English (en)
Inventor
Craig D Boyle
Anima Ghosal
Wei Tong
Swapan K Chowdhury
Shmuel Zbaida
Mark A Wirth
Kevin B Alton
James E Patrick
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1082739A1 publication Critical patent/HK1082739A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK06105215A 2003-07-31 2006-05-03 Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction HK1082739A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49221803P 2003-07-31 2003-07-31
PCT/US2004/024525 WO2005012303A1 (fr) 2003-07-31 2004-07-29 Metabolite de l'inhibiteur de xanthine phosphodiesterase 5 et derives de ce metabolite, utiles dans le traitement de la dyserection

Publications (1)

Publication Number Publication Date
HK1082739A1 true HK1082739A1 (en) 2006-06-16

Family

ID=34115611

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06105215A HK1082739A1 (en) 2003-07-31 2006-05-03 Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction

Country Status (11)

Country Link
US (1) US7312223B2 (fr)
EP (1) EP1648895B1 (fr)
JP (1) JP2007500714A (fr)
CN (1) CN1860119A (fr)
AT (1) ATE363483T1 (fr)
CA (1) CA2533715A1 (fr)
DE (1) DE602004006756T2 (fr)
ES (1) ES2284056T3 (fr)
HK (1) HK1082739A1 (fr)
MX (1) MXPA06001195A (fr)
WO (1) WO2005012303A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DK1509525T5 (da) * 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor
CA2577442A1 (fr) * 2004-08-17 2006-03-02 The Johns Hopkins University Compositions d'inhibiteur pde5 et methodes de traitement des troubles cardiaques
KR20090087795A (ko) * 2008-02-13 2009-08-18 한양대학교 산학협력단 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US20100261737A1 (en) * 2009-04-10 2010-10-14 Medtronic Vascular, Inc. Method of Treating Erectile Dysfunction
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
CN106770618A (zh) * 2015-11-20 2017-05-31 中国康复研究中心 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
ZA914727B (en) * 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
EP0563168B1 (fr) * 1990-12-21 2000-07-05 Beecham Group Plc Derives de xanthine
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
AU681875B2 (en) * 1993-02-26 1997-09-11 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DK1509525T5 (da) * 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor
ES2299720T3 (es) * 2002-05-31 2008-06-01 Schering Corporation Formas polimorfas de un inhibidor de xantina-fosfodiesterasa v.

Also Published As

Publication number Publication date
EP1648895A1 (fr) 2006-04-26
ATE363483T1 (de) 2007-06-15
MXPA06001195A (es) 2006-04-11
EP1648895B1 (fr) 2007-05-30
ES2284056T3 (es) 2007-11-01
WO2005012303A1 (fr) 2005-02-10
CA2533715A1 (fr) 2005-02-10
DE602004006756T2 (de) 2008-01-24
US7312223B2 (en) 2007-12-25
US20050026939A1 (en) 2005-02-03
CN1860119A (zh) 2006-11-08
JP2007500714A (ja) 2007-01-18
DE602004006756D1 (de) 2007-07-12

Similar Documents

Publication Publication Date Title
HK1082739A1 (en) Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment oferectile dysfunction
DE60019919T2 (de) Hydrochloride kondensierter heterozyklen
JP2017105819A5 (fr)
RU2009114857A (ru) Гетероциклические органические соединения
JP2010511727A5 (fr)
CN108697807A (zh) 代谢功能障碍引起的肿瘤的治疗
JP2018505859A5 (fr)
JP2016523243A5 (fr)
CN107286146B (zh) 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
JP2010511727A (ja) アデノシン受容体アンタゴニストとしての置換ピリミジン
JP2019513126A5 (fr)
WO2008002902A3 (fr) Antagonistes du récepteur de l'adénosine a2b
CN100999517A (zh) 吡唑甲酰胺衍生物,药物组合物和其制备方法
RU2009135821A (ru) Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции
JP2024534580A (ja) 代謝障害を処置する方法
NZ597222A (en) Substituted 8-[6-Amino-3-Pyridyl]Xanthines
JP2007500714A5 (fr)
Zuo et al. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists
YU12003A (sh) Novi derivati aminocikloheksana
EP2094285B1 (fr) Extrait spécifique et son utilisation pour atténuer la perte de guanosine monophosphate (cgmp) cyclique
JPH0273015A (ja) 置換３，４‐ジヒドロ‐２ｈ‐ベンゾピラン類の肺の閉鎖性機能障害および／または輸出尿路の障害の治療薬としての使用
Berk et al. New 8-substituted xanthiene derivatives as potent bronchodilators
Boss 20 Years of Medicinal Chemistry–Always Look at the Bright Side (of Life)
Saxena et al. Essential Hypertension: Pathophysiology& Management (Current View)
Ran et al. Scaffold-based design of xanthine as highly potent inhibitors of DPP-IV for improving glucose homeostasis in DIO mice

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100729